AWH Capital L.P. Purchases Shares of 625,000 Evolus, Inc. $EOLS

Key Points

• AWH Capital initiated a 625,000-share position in Evolus, valued at approximately $4.34 million and representing 0.95% of the company. Institutional investors collectively own 90.69% of Evolus.
• Analyst sentiment is broadly positive: four analysts rate the stock a Buy, one rates it Hold, and one rates it Sell. Evolus has a consensus rating of “Moderate Buy” and an average price target of $14.50.
• Evolus shares opened at $8.88, near their 52-week high of $9.12, with a market capitalization of approximately $586.5 million. The stock’s 50-day and 200-day moving averages are $7.04 and $5.91, respectively.

AWH Capital L.P. purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 625,000 shares of the company's stock, valued at approximately $4,337,500. Evolus makes up about 0.0% of AWH Capital L.P.'s investment portfolio, making the stock its 17th biggest position. AWH Capital L.P. owned 0.95% of Evolus as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Larson Financial Group LLC lifted its holdings in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock worth $33,000 after buying an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Evolus in the fourth quarter worth $34,000. Wexford Capital LP purchased a new position in shares of Evolus in the third quarter worth $37,000. Legal & General Group Plc purchased a new position in shares of Evolus in the second quarter worth $40,000. Finally, Aquatic Capital Management LLC purchased a new position in shares of Evolus in the third quarter worth $48,000. Hedge funds and other institutional investors own 90.69% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Weiss Ratings raised shares of Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 15th. BTIG Research reissued a "buy" rating and issued a $13.00 target price on shares of Evolus in a report on Wednesday, June 17th. Wall Street Zen raised shares of Evolus from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Evolus in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Evolus currently has a consensus rating of "Moderate Buy" and an average price target of $14.50.

Evolus Price Performance

Evolus stock opened at $8.88 on Friday. The company has a market cap of $586.52 million, a price-to-earnings ratio of -17.08 and a beta of 1.35. The firm's fifty day moving average is $7.04 and its 200 day moving average is $5.91. Evolus, Inc. has a 52-week low of $3.86 and a 52-week high of $9.12.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source